Monday, February 6, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

RFI – Chemical Agent Countermeasure Support

by Global Biodefense Staff
May 14, 2015
Joint Project Manager Medical Countermeasure Systems

The DoD Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office  has a requirement to develop and deliver FDA licensed butyrylcholinesterase (BChE).

BChE is a bioscavenger prophylactic countermeasure against organophosphate nerve agents, binding nerve agent in the bloodstream before it can exert effects in the nervous system.

DynPort Vaccine Company LLC, a CSC company, is the prime contractor for this effort.

On behalf of DVC, the MCS-CDP JPMO is seeking interest by research or commercial entities with the capability to perform process development activities at small scale to intermediate scale in order to identify a source raw material and process to fit to the commercial scale requirements of this DoD contract.

Source raw material and historical manufacturing information will be provided by DVC.

Capability requirements include:

  • Acceptance of human plasma derived source material into the process development facility
  • Storage of the source material at -80OC (up to 50kg of starting source material per run)
  • Development and optimization of the purification process at the 1-5kg scale and 50kg scale
  • Manufacture and testing of an interim Reference Standard (RS) to support process development and optimization activities
  • Implementation of analytical methods to be used during process development and RS production effort, including but not limited to total protein, enzyme activity, and HPLC-based methods.
  • Project Management support including status meetings and monthly reports with technical, schedule and cost elements

In addition, the selected contractor must be able to meet a November 2015 down select of source material and process for commercial scale manufacturing.

Further details are available via Solicitation Number: W911QY-15-S-DAMD17.

Tags: AntitoxinsBioscavengersJPEO-CBRNDRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC